PT  - JOURNAL ARTICLE
AU  - TORU AOYAMA
AU  - YUKIO MAEZAWA
AU  - ITARU HASHIMOTO
AU  - YASUSHI RINO
AU  - TAKASHI OSHIMA
TI  - Clinical Impact of Nutrition and Inflammation Assessment Tools in Pancreatic Cancer Treatment
AID  - 10.21873/anticanres.16572
DP  - 2023 Sep 01
TA  - Anticancer Research
PG  - 3849--3860
VI  - 43
IP  - 9
4099  - http://ar.iiarjournals.org/content/43/9/3849.short
4100  - http://ar.iiarjournals.org/content/43/9/3849.full
SO  - Anticancer Res2023 Sep 01; 43
AB  - Perioperative adjuvant treatment and complete resection is the standard treatment for resectable pancreatic cancer and systemic chemotherapy is standard treatment for unresectable pancreatic cancer. To improve the survival of patients with pancreatic cancer, it is necessary to identify promising biomarkers to optimize the treatment. The availability of biomarkers may allow patients to receive a more aggressive or less toxic treatment. Recent studies showed that the inflammatory and nutritional status perioperatively and/or during chemotherapy affect short and long-term oncological outcomes in pancreatic cancer. Introduction of inflammatory and nutritional status evaluation in pancreatic cancer treatment might improve the postoperative surgical complications or chemotherapy-induced adverse events. However, to introduce these various nutritional and inflammation assessment tools in daily clinical practice, it is necessary to understand the characteristics of each nutrition and inflammation assessment tool. This review summarizes the background, current status, and future perspectives of nutrition and inflammation assessment tools in pancreatic cancer treatment.